

IN THE SPECIFICATION:

Please insert before paragraph [001] the following:

CROSS REFERENCED RELATED APPLICATION

[001] This application is a divisional application of U.S. Application 09/214,851 filed September 9, 1999 which is a National Stage of International Application No. PCT/CA97/00506, filed July 17, 1997, which was published in English and claimed priority to provisional application 60/021,940 filed on July 17, 1996 and is hereby incorporated by reference in its entirety.

Please replace paragraph [067] with the following replacement paragraph:

[067] Substances which inhibit transcription and/or translation of the gene encoding CYP2A6 include a nucleic acid sequence encoding the CYP2A6 gene (see Figure 2A, Genbank Accession No. HSU22027 (SEQ ID NO:1)) or parts thereof (e.g., the region which is about 20 nucleotides on either side of nucleotide 790 (ATG), and the splice sites 1237, 2115, 2499, 3207, 4257, 4873, 5577, and 6308), inverted relative to their normal orientation for transcription - i.e., antisense CYP2A6 nucleic acid molecules. Such antisense nucleic acid molecules may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed with CYP2A6 mRNA or the CYP2A6 gene. The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.--

Please replace paragraph [076] with the following replacement paragraph:

[076] Substances which inhibit transcription and/or translation of the gene encoding CYP2B6 include a nucleic acid sequence encoding the CYP2B6 gene (see Figure 2B, GenBank

Accession No. HSP452B6 for the mRNA sequence of CYP2B6 (SEQ ID NO:2), or parts thereof (e.g., the region which is on either side of nucleotide 9 (ATG), and the sites 111, 274, 424, 585, 762, 904, 1092, and 1234 nt), inverted relative to their normal orientation for transcription - i.e., antisense CYP2B6 nucleic acid molecules. Such antisense nucleic acid molecules may be produced and introduced into cells using conventional procedures as described herein.--

Please replace the Table on page 49 under paragraph [152] with the following replacement Table:

--

Sequence data for antisense oligodeoxynucleotides																									
NAME*	START*	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	END	SEQ ID NO
ASO#15	-25	T	A	G	A	G	G	G	A	T	G	A	T	A	G	A	T	G	G	T	G	A	C	-4	3
ASO#13	171	C	T	T	C	A	T	G	A	G	G	G	A	G	T	T	G	T	A	C				189	4
ASO#25	190	G	G	C	C	A	T	A	G	C	G	C	T	C	A	C	T	G	A	T				208	5
ASO#23	333	C	C	A	T	A	G	C	C	T	T	T	G	A	A	G	A	C	C	C	A	G		353	6
MSO#23	333	C	C	C	C	A	G	C	C	T	T	T	G	A	A	G	A	C	A	T	A	G		353	7

--

On page 50, above paragraph [155] please replace the Table with the following replacement Table:

--

Assay	Name	Sequence (5'-3')
CYP2A6*2 (v ₁) and CYP2A6*3 (v ₂)	F4	CCTCCCTTGCTGGCTGTGTCCCAAGCTTAGGC (SEQ ID NO: 8)
	R4	CGCCCCCTTCCTTTCCGCCATCCTGCCCCCAG (SEQ ID NO: 9)
	E3F	GCGTGGTATTCAGCAACGGG (SEQ ID NO: 10)
	E3R	TCGTGGGTGTTTTCCTTC (SEQ ID NO: 11)

--

AMENDMENTS TO THE DRAWINGS

Applicants submit herewith proposed amendments to Figures 2A and 2B under 37 C.F.R. § 1.121. The proposed amendments to the figures are presented in red ink on a separate sheet for each respective figure, for approval by the Examiner. Applicants respectfully request consideration of the proposed amendments to the Figures and notification of acceptance of the Figure amendments by the Examiner.

Attachment: 12 pages of replacement Sheets